Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandria M Chan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
RSC Medicinal Chemistry|May 28, 2021
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6Alexandria M Chan, Steven Fletcher
Drug Development Research|October 25, 2022
1-Sulfonylated 1,2,3,4-tetrahydroquinoline-6-carboxylic acids as simple, readily-accessible MCL-1 inhibitorsLijia Chen, Alexandria M Chan, Paul T Wilder, et al.
RSC Medicinal Chemistry|September 12, 2022
Recent applications of covalent chemistries in protein-protein interaction inhibitorsAlexandria M Chan, Christopher C Goodis, Elie G Pommier, et al.
Bioorganic & Medicinal Chemistry|April 6, 2024
Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitorsAlexandria M Chan, Ashley Mitchell, Lena Grogan, et al.
Drug Development Research|May 15, 2025
Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 InhibitorsAlexandria M Chan, Christian Eberly, Brandon Drennen, et al.
European Journal of Medicinal Chemistry|January 15, 2025
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitorsChristopher C Goodis, Christian Eberly, Alexandria M Chan, et al.
Journal of Proteome Research|August 27, 2025
diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction ProfilingKathryn Woods, Alexandria M Chan, Thankhoe A Rants'o, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction ProfilingKathryn Woods, Thankhoe A Rants'o, Alexandria M Chan, et al.
ACS Medicinal Chemistry Letters|January 14, 2026
First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma AgentsAlexandria M Chan, Brandon D Lowe, Andrea L Cottingham, et al.
Cells|January 9, 2026
Multiomic Analyses Reveal Brainstem Metabolic Changes in a Mouse Model of Dravet SyndromeAshwini Sri Hari, Alexandria M Chan, Audrey Scholl, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
RSC Medicinal Chemistry|May 28, 2021
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6Alexandria M Chan, Steven Fletcher
Drug Development Research|October 25, 2022
1-Sulfonylated 1,2,3,4-tetrahydroquinoline-6-carboxylic acids as simple, readily-accessible MCL-1 inhibitorsLijia Chen, Alexandria M Chan, Paul T Wilder, et al.
RSC Medicinal Chemistry|September 12, 2022
Recent applications of covalent chemistries in protein-protein interaction inhibitorsAlexandria M Chan, Christopher C Goodis, Elie G Pommier, et al.
Bioorganic & Medicinal Chemistry|April 6, 2024
Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitorsAlexandria M Chan, Ashley Mitchell, Lena Grogan, et al.
Drug Development Research|May 15, 2025
Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 InhibitorsAlexandria M Chan, Christian Eberly, Brandon Drennen, et al.
European Journal of Medicinal Chemistry|January 15, 2025
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitorsChristopher C Goodis, Christian Eberly, Alexandria M Chan, et al.
Journal of Proteome Research|August 27, 2025
diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction ProfilingKathryn Woods, Alexandria M Chan, Thankhoe A Rants'o, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction ProfilingKathryn Woods, Thankhoe A Rants'o, Alexandria M Chan, et al.
ACS Medicinal Chemistry Letters|January 14, 2026
First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma AgentsAlexandria M Chan, Brandon D Lowe, Andrea L Cottingham, et al.
Cells|January 9, 2026
Multiomic Analyses Reveal Brainstem Metabolic Changes in a Mouse Model of Dravet SyndromeAshwini Sri Hari, Alexandria M Chan, Audrey Scholl, et al.
Pageof 1